A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors
Clinical trial NCT06299124 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06299124
- Sponsor
- Regor Pharmaceuticals Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-04-17
- Primary completion
- 2025-07-30
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.